Envoy Medical Faces Delisting Concerns

TL;DR

Envoy Medical might get delisted, stock watch!

AI Summary

Envoy Medical, Inc. filed an 8-K on August 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of August 26, 2025. The company, previously known as Anzu Special Acquisition Corp I, is incorporated in Delaware and operates in the orthopedic, prosthetic & surgical appliances & supplies industry.

Why It Matters

This filing indicates potential issues with Envoy Medical's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event for a publicly traded company.

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant
• Anzu Special Acquisition Corp I (company) — Former company name
• August 26, 2025 (date) — Date of earliest event reported
• August 29, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
• $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
• $35,000,000 — securities did not meet the minimum of $35,000,000 (the "MVLS Requirement") for the period

Filing Documents

• ea0255235-8k_envoy.htm (8-K) — 30KB
• 0001213900-25-082608.txt ( ) — 238KB
• coch-20250826.xsd (EX-101.SCH) — 4KB
• coch-20250826_def.xml (EX-101.DEF) — 26KB
• coch-20250826_lab.xml (EX-101.LAB) — 36KB
• coch-20250826_pre.xml (EX-101.PRE) — 25KB
• ea0255235-8k_envoy_htm.xml (XML) — 6KB

01. Notice of Delisting or Failure to Satisfy a Continued

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 25, 2025, Envoy Medical, Inc. (the "Company") received a deficiency notification letter (the "Notification Letter") from The Nasdaq Stock Market ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the market value of the Company's listed securities did not meet the minimum of $35,000,000 (the "MVLS Requirement") for the period of 30 consecutive business days between January 7, 2025 and February 24, 2025. The Notification Letter provided a 180 day period for the Company to become compliant with the MVLS Requirement. On August 26, 2025, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period. The determination letter informed the Company that it can request a hearing regarding Nasdaq's determination with a Hearings Panel (the "Panel") by September 2, 2025 to discuss how the Company believes it will regain compliance and why the Company believes the Hearing Panel should grant an extension. If the Company did not make a request to the Hearings Panel, the trading of the Company's securities would be suspended at the opening of business on September 4, 2025. The Company submitted a hearing request to the Panel on August 29, 2025. The request itself will stay any trading suspension of the Company's securities or the potential filing of a Form 25-NSE until after the Panel meeting is held and the Panel provides a decision. The Company is optimistic that it will be able to demonstrate to the Panel several different viable and relatively near-term pathways to regain compliance (including, in part, the recent resetting of its balance sheet with the full extinguishment of its debt), however, there can be no assurance that the Panel will grant the Company's request fo

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as "anticipated," "forward," "will," "would," "could," "may," "intend," "remain," "potential," "prepare," "expected," "believe," "plan," "seek," "continue," "estimate," "and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: our ability to cure any deficiencies in compliance with the MVLS Requirement, or other Nasdaq listing rules, or maintain compliance with other Nasdaq listing rules; our ability to successfully appeal the determination made by the Listing Qualification Department of Nasdaq to a Hearings Panel; that grant by Nasdaq for additional compliance periods in which to seek to regain compliance with the MVLS Requirement; our ability to ultimately obtain relief or extended periods to regain compliance from Nasdaq, if necessary, or to meet applicable Nasdaq requirements for any such relief or extension; risks related to the substantial costs and diversion of management's attention and resources due to these matters, and those risks and uncertainties identified in the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. August 29, 2025 By: /s/ Brent Lucas Brent Lucas Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR